Delivery Order SPE2DB22D3016-SPE2DB25FBKA1
- Not listed
- The Defense Logistics Agency awarded a $34,953.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injector pharmaceutical supply. The contract, executed on September 17, 2025, represents a non-competitive delivery order with an ultimate completion date of September 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's substantial...
- The Defense Logistics Agency awarded a $25,765.04 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of ENBREL 50 MG/ML SureClick auto-injectors. The contract, which represents a child order under a larger procurement vehicle, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 4, 2025. This delivery order was competitively awarded with no set-aside designation,...
- The Defense Logistics Agency awarded a $13,880.31 firm fixed price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors, with an ultimate completion date of September 15, 2025. This non-competitive delivery order leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply agreement running through December 2026. The product will be performed at the...
- The Defense Logistics Agency awarded a $39,049.72 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price contract serves as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $35,070.68 firm fixed price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors, with an ultimate completion date of July 23, 2025. This non-set-aside contract was competitively awarded on July 22, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a $15,850.12 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for ENBREL 50 mg/ml SureClick auto-injectors, with an ultimate completion date of August 14, 2025. This non-set-aside contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $13,844.92 delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This non-set-aside, competitively awarded contract utilized firm fixed pricing and was completed on July 24, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's established role as a critical pharmaceutical supplier to the...
- The Defense Logistics Agency awarded a delivery order valued at $9,253.56 to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL SureClick auto-injectors, with a completion date of July 15, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $10,451.31 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors on July 11, 2025, with performance completion scheduled for July 14, 2025. This non-competitive delivery order, issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, represents a continuation of the company's critical role as a pharmaceutical supplier to federal military and...
- The Defense Logistics Agency awarded a $39,057.22 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick auto-injectors, with an ultimate completion date of July 7, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBKA1Delivery Order
The Defense Logistics Agency awarded a $90,119.95 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of ENBREL 50 MG/ML SureClick auto-injectors. This non-competitive delivery order is set to be completed by September 19, 2025, with performance occurring at the vendor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills this order under its broader service relationship with the Defense Logistics Agency's medical supply chain. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This comprehensive contract vehicle enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. ENBREL is a biologic immunosuppressant used to treat rheumatoid arthritis and other autoimmune conditions, representing the type of specialty pharmaceutical product the company routinely delivers to support Department of Defense and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $90.1k | 9/18/25 |